Precipio Inc. (PRPO)
PRPO trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1043961/000110465926036878/0001104659-26-036878-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PRPO on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001043961 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $24.0M |
| Net income | -$363K |
| Operating income | -$1.2M |
| Net margin | -1.5% |
| Operating margin | -5.0% |
| Revenue growth | +29.8% |
| Cash | $2.7M |
| Total assets | $21.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company's ability to continue as a going concern for the next twelve months from the date these condensed consolidated financial statements were issued." | 10-Q 2026-11-10 |
| Cash and burn | $3.6M cash; operating cash flow $425K a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,792,935 (2026-11-06); 1,752,007 a year earlier; 1,420,125 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., New Haven, Connecticut, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1K, sold $100K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $7.3M | -$8K | $610K | $3.6M | $347K | $27.8M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $7.0M | -$219K | $660K | $3.1M | $325K | $27.2M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $6.7M | -$1.4M | $64K | $2.6M | $70K | $25.8M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $6.7M | $526K | $366K | $2.7M | $83K | $24.0M | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $6.8M | -$79K | $10K | $2.3M | $85K | $22.8M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $5.7M | $74K | $353K | $1.1M | $91K | $21.2M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $4.9M | -$884K | -$44K | $1.0M | $217K | $20.0M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $5.5M | -$365K | $565K | $1.4M | $383K | $18.5M | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-04-08 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report FORM 8-K | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +18.9% |
| 1 month | -2.0% |
| 3 months | -4.7% |
| Year to date | -3.7% |
| 1 year | +13.4% |
| From 52-week high | -31.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EYPT | EyePoint Inc. | $0.3076 | +0.52% | $35.0M |
| RPID | Rapid Micro Biosystems Inc. | $0.7400 | +13.67% | $37.1M |
| HBIO | Harvard Bioscience Inc. | $8.91 | -5.96% | $40.7M |
| CIRC | Circle8 Group Inc. | $0.1702 | -7.30% | $20.0M |
| SEER | Seer Inc. | $1.48 | -5.73% | $82.6M |
| BNGO | Bionano Genomics Inc. | $0.9400 | -6.00% | $13.1M |
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
| ASTC | Astrotech Corporation (DE) | $3.76 | -10.48% | $8.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier